Molecular Diagnostics in Cardiovascular Diseases: From Biomarkers to Personalized Medicine

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 5199

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Cardiovascular Sciences, Medical School, University of Birmingham, Birmingham, UK
Interests: atrial fibrillation; chronic heart failure; heart failure; echocardiography; clinical car-diology

Special Issue Information

Dear Colleagues,

Cardiovascular diseases (CVDs) remain the leading cause of death globally, highlighting the urgent need for innovative diagnostic tools that enable early detection, risk stratification, and personalized therapy. This Special Issue aims to explore the evolving role of molecular diagnostics in transforming cardiovascular care, from traditional biomarkers to advanced genomic, proteomic, and metabolomic technologies. As precision medicine becomes an integral part of clinical practice, identifying and validating reliable molecular markers is critical to guiding targeted interventions and improving outcomes.

We invite original research articles and reviews focused on the discovery, validation, and clinical application of molecular diagnostics in cardiovascular settings. Topics of interest include, but are not limited to, the following: circulating biomarkers (e.g., troponins, natriuretic peptides, sST2, and galectin-3), genetic and epigenetic profiling, RNA-based diagnostics, multi-omics integration, liquid biopsy approaches, biomarker-guided therapy, and the use of artificial intelligence in biomarker discovery and risk prediction. Studies addressing molecular diagnostics in specific conditions such as heart failure, coronary artery disease, myocarditis, and cardiomyopathies are especially welcome. This Special Issue seeks to provide a comprehensive overview of the current landscape and future directions in molecular diagnostics for CVDs, with an emphasis on translational relevance and clinical impact.

Dr. Otilia Țica
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • biomarkers
  • precision medicine
  • diagnostics
  • heart failure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 415 KB  
Review
Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring
by Dimitrios Raptis, Shiny Teja Kolli, Sonal Agarwal, Praveen Kumar Komminni, Prashamsha Bhattarai, Prinka Hablani, Rahul Kumar, Petras Das, Martin McIntosh, Michail Kladas, Priyanka Gokulnath and Michail Spanos
Diagnostics 2025, 15(18), 2346; https://doi.org/10.3390/diagnostics15182346 - 16 Sep 2025
Viewed by 2172
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition linked to obesity, diabetes, and metabolic syndrome, and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Current diagnostic standards such as liver biopsy are invasive and unsuitable for routine screening. Liquid biopsy, [...] Read more.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition linked to obesity, diabetes, and metabolic syndrome, and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Current diagnostic standards such as liver biopsy are invasive and unsuitable for routine screening. Liquid biopsy, particularly through analysis of extracellular RNAs (exRNAs), including microRNAs (e.g., miR-122, miR-21, miR-34a), long non-coding RNAs, and tRNA-derived fragments, offers a promising non-invasive alternative. These exRNAs, released from hepatocytes and carried in blood via extracellular vesicles or protein complexes, can be detected using techniques like RNA sequencing, qRT-PCR, and droplet digital PCR. These biomarkers correlate with histologic severity, fibrosis stage, and treatment response, and have shown promising diagnostic utility; however, their performance may differ across various populations and disease stages. Despite their potential, clinical translation is limited by a lack of standardization and large-scale validation. This review outlines recent advances in exRNA-based diagnostics for MASLD and MASH, emphasizing their role in early detection, disease monitoring, and the shift toward personalized hepatology. Full article
Show Figures

Graphical abstract

21 pages, 1736 KB  
Review
Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine
by Ovidiu Țica and Otilia Țica
Diagnostics 2025, 15(14), 1807; https://doi.org/10.3390/diagnostics15141807 - 17 Jul 2025
Cited by 14 | Viewed by 2630
Abstract
Heart failure (HF) is a global health burden characterized by high morbidity and mortality, necessitating advancements in diagnostic and therapeutic approaches. Molecular diagnostics, encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenetics, offer unprecedented insights into HF pathogenesis, aiding early diagnosis, risk stratification, and personalized [...] Read more.
Heart failure (HF) is a global health burden characterized by high morbidity and mortality, necessitating advancements in diagnostic and therapeutic approaches. Molecular diagnostics, encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenetics, offer unprecedented insights into HF pathogenesis, aiding early diagnosis, risk stratification, and personalized management. This state-of-the-art review critically examines recent developments in molecular diagnostics in HF, evaluates their translational potential, and highlights key challenges in clinical implementation. Emerging tools such as liquid biopsy, multi-omics integration, and artificial intelligence (AI)-driven platforms are explored. We propose strategies to enhance clinical translation, equity in access, and utility in guiding treatment, thereby advancing precision cardiovascular medicine Full article
Show Figures

Graphical abstract

Back to TopTop